Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
US companies are reshoring manufacturing operations & investing billions in the country, led by Apple & Nvidia for tech, J&J & Eli Lilly for healthcare, Anheuser-Busch for beer, & Cra-Z-Art for toys. Detroit & beyond are benefiting from this trend.
Following a third failed bankruptcy maneuver by Johnson & Johnson (NYSE: JNJ), trial lawyers with Dallas-based Nachawati Law Group have filed three new lawsuits on behalf of women who developed cancer after prolonged use of the company’s talc-based products.
Rising bond yields and uncertain politics make 'safety' stocks less appealing, says Jim Cramer. Even Procter & Gamble and Johnson & Johnson suddenly feel shaky to the market guru.
Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th, 2025. Management will participate in a Fireside Chat at 3:20 p.m. Eastern Time.
Mark Cuban, the billionaire entrepreneur, challenged Trump-supporter and political activist Charlie Kirk's stance on high drug prices, asserting that Pharmacy Benefit Managers (PBMs) are the main culprits, not Big Pharma.
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription drug prices.
The company said that 66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational oral Icotrokinra achieved site-specific clear or almost clear skin at week 16.
